

COPY

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Robert G. Petit, II et al.

Examiner: Unknown

Serial No.:

09/993,465

Group Art Unit: 1646

Filed:

November 14, 2001

Docket: 781.014US1

Title:

IMPROVED CELLULAR UPTAKE OF BIOACTIVE AGENTS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 et. seq., the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(b), it is believed that no fee or statement is required with the Supplemental Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Account No. 19-0743 in order to have this Supplemental Information Disclosure Statement considered.

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted, ROBERT G. PETIT, II ET AL. By their Representatives, SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A. P.O. Box 2938 Minneapolis, MN 55402 (612) 373-6903

Date 8-14-02

Warren D. Woessner, Ph.D.

Reg. No. 30,440

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231, on this 4 day of August, 2002.

Anne M. Richards

Name

ignature





PTC/S9/08A(10-01) Approved for use through 10/31/2002. OMB 651-0031

Substitute for form 1449A/PTO Complete if Known INFORMATION DISCLOSURE Applicati n Number 09/993465 STATEMENT BY APPLICANT (Use as many sheets as necessary) Filing Date November 14, 2001 **First Named Inventor** Petit, Robert **Group Art Unit** 1646 Unknown **Examiner Name** Attorney Docket No: 00781.014US1 Sheet 1 of 1

US PATENT DOCUMENTS								
Examiner initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date if Appropriate		
•••	US-5726146	03/10/1998	Almada, Anthony L., et al	514	2	12/06/1994		
	US-5849335	12/15/1998	Ballevre, Olivier, et al	424	535	06/02/1997		

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T ²	

	OTHE	R DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		STEENGE, G. R., et al., "Stimulatory Effect of Insulin on Creatine Accumulation in Human Skeletal Muscle", American Journal of Physiology, Vol. 275, (Dec. 1998), E974-E979	